Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using specific cytotoxics with a targeted mind.

Angelo Di Leo1, Wederson M Claudino, Marta Pestrin

  • 1Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy. adileo@us14.toscana.it

Breast (Edinburgh, Scotland)
|August 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing.

Genome medicine·2026
Same author

ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 4).

Breast (Edinburgh, Scotland)·2025
Same author

Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines.

NPJ breast cancer·2025
Same author

Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations.

Future oncology (London, England)·2025
Same author

The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report.

Critical reviews in oncology/hematology·2025

Predicting breast cancer treatment response involves identifying molecular markers for specific cytotoxic drugs. Research explores markers for anthracyclines, taxanes, and DNA-damaging agents to personalize chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Clinical activity of cytotoxic agents varies among breast cancer patients.
  • This variability suggests distinct breast cancer subtypes with differential drug sensitivities.
  • Molecular markers may predict patient response to specific chemotherapy agents.

Purpose of the Study:

  • To review molecular markers that predict response to anthracyclines, taxanes, and DNA-damaging agents in breast cancer.
  • To summarize pre-clinical and early clinical evidence for these predictive markers.
  • To highlight the potential of a targeted approach to chemotherapy in breast cancer treatment.

Main Methods:

  • Review of pre-clinical and early clinical data on molecular markers and cytotoxic drug activity.

Related Experiment Videos

  • Categorization of evidence based on drug class: anthracyclines, taxanes, and DNA-damaging agents.
  • Discussion of gene aberrations, protein expression, and mutations as potential predictive markers.

    • Main Results:

    • Topoisomerase II (topo II) gene aberrations/overexpression may predict anthracycline response.
    • HER-2 amplification and p-53 mutations are potential markers for taxanes, though further studies are needed.
    • BRCA 1 mutations may indicate increased sensitivity to DNA-damaging agents like platinum-derivates.

    Conclusions:

    • Molecular markers show promise in predicting breast cancer response to specific cytotoxic agents.
    • Further large-scale clinical studies are required to validate the predictive value of these markers.
    • A targeted chemotherapy approach, guided by molecular profiling, could enhance treatment efficacy in breast cancer.